The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...
The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback